April 2 (Reuters) - Quoin Pharmaceuticals Ltd <2EBy.BE>::
*QUOIN PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE ‘WHOLE BODY’ CLINICAL DATA FROM ONGOING PEDIATRIC NETHERTON SYNDROME STUDY AND APPROVAL TO INITIATE TESTING OF A SECOND PEDIATRIC PATIENT
*QUOIN PHARMACEUTICALS LTD - SUBJECT'S SKIN ALMOST COMPLETELY HEALED AFTER 6 WEEKS OF QRX003
*QUOIN PHARMACEUTICALS LTD - NO ADVERSE EVENTS REPORTED AFTER 6 WEEKS OF QRX003 TREATMENT
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 02-APR-202511:30:01.033 GMT